biguanides has been researched along with Neuroblastoma in 11 studies
Biguanides: Derivatives of biguanide (the structure formula HN(C(NH)NH2)2) that are primarily used as oral HYPOGLYCEMIC AGENTS for the treatment of DIABETES MELLITUS, TYPE 2 and PREDIABETES.
biguanides : A class of oral hypoglycemic drugs used for diabetes mellitus or prediabetes treatment. They have a structure based on the 2-carbamimidoylguanidine skeleton.
Neuroblastoma: A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The pharmacological characteristics of 5-HT3 receptor (5-hydroxytryptamine3 receptor) recognition sites labelled with [3H]-(S)-zacopride and [3H]granisetron in membranes prepared from NG108-15 neuroblastoma-glioma cells were directly compared to investigate further differences in the binding characteristics of these two radioligands." | 7.68 | Differential binding characteristics of agonists at 5-HT3 receptor recognition sites in NG108-15 neuroblastoma-glioma cells labelled by [3H]-(S)-zacopride and [3H]granisetron. ( Barnes, JM; Barnes, NM, 1993) |
| " In both N1E-115 neuroblastoma cells and human embryonic kidney 293 cells stably expressing the 5-HT3 receptor As subunit, (+)-verapamil, (-)-verapamil, diltiazem, and nimodipine caused reversible and concentration-dependent (IC50 = 2." | 3.69 | Direct inhibition of 5-hydroxytryptamine3 receptors by antagonists of L-type Ca2+ channels. ( Gunthorpe, MJ; Hargreaves, AC; Lummis, SC; Taylor, CW, 1996) |
| "The pharmacological characteristics of 5-HT3 receptor (5-hydroxytryptamine3 receptor) recognition sites labelled with [3H]-(S)-zacopride and [3H]granisetron in membranes prepared from NG108-15 neuroblastoma-glioma cells were directly compared to investigate further differences in the binding characteristics of these two radioligands." | 3.68 | Differential binding characteristics of agonists at 5-HT3 receptor recognition sites in NG108-15 neuroblastoma-glioma cells labelled by [3H]-(S)-zacopride and [3H]granisetron. ( Barnes, JM; Barnes, NM, 1993) |
| " In the presence of 100 microM 2-Me5-HT, the upper part of the 5-HT dose-response curve was shifted to the right but reached the same maximum value as in the absence of 2-Me5-HT." | 1.28 | The agonist properties of m-chlorophenylbiguanide and 2-methyl-5-hydroxytryptamine on 5-HT3 receptors in N1E-115 neuroblastoma cells. ( Lummis, SC; Martin, IL; Sepúlveda, MI, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (72.73) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Urban-Wójciuk, Z | 1 |
| Graham, A | 1 |
| Barker, K | 1 |
| Kwok, C | 1 |
| Sbirkov, Y | 1 |
| Howell, L | 1 |
| Campbell, J | 1 |
| Woster, PM | 1 |
| Poon, E | 1 |
| Petrie, K | 1 |
| Chesler, L | 1 |
| Stewart, A | 1 |
| Davies, PA | 1 |
| Kirkness, EF | 1 |
| Safa, P | 1 |
| Hales, TG | 1 |
| Lummis, SC | 4 |
| Sepúlveda, MI | 3 |
| Kilpatrick, GJ | 1 |
| Baker, J | 1 |
| Barnes, JM | 1 |
| Barnes, NM | 1 |
| Toral, J | 1 |
| Hu, W | 1 |
| Critchett, D | 1 |
| Solomon, AJ | 1 |
| Barrett, JE | 1 |
| Sokol, PT | 1 |
| Ziai, MR | 1 |
| Hargreaves, AC | 1 |
| Gunthorpe, MJ | 1 |
| Taylor, CW | 1 |
| van Hooft, JA | 1 |
| Kreikamp, AP | 1 |
| Vijverberg, HP | 1 |
| Rondé, P | 2 |
| Nichols, RA | 2 |
| Boess, FG | 1 |
| Martin, IL | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Preventative Trial of DFMO (Eflornithine HCl) as a Single Agent in Patients With High Risk Neuroblastoma in Remission[NCT02395666] | Phase 2 | 140 participants (Actual) | Interventional | 2015-03-05 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Pharmacokinetic assay AUC(0-6 hr)/D~Samples drawn at 5 timepoints: (0 (pre dose), 30min, 1 hour, 3 hours, and 6 hours post-dose) on two different days" (NCT02395666)
Timeframe: 0 (pre dose), 30min, 1 hour, 3 hours, and 6 hours post-dose on two different days
| Intervention | hr*ng/mL (Mean) |
|---|---|
| Study Subjects Consented to PK Collection | 47024 |
To continue to determine the safety and tolerability of DFMO as a single agent and in pediatric and young adult patients with high risk neuroblastoma that is in remission. (NCT02395666)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| DFMO Twice Daily | 57 |
To evaluate the preventative activity of DFMO as a single agent in patients that are in remission based on: Event free survival (EFS) (NCT02395666)
Timeframe: 2 Years
| Intervention | percentage of subjects without an event (Mean) |
|---|---|
| Stratum 1 | 84 |
| Stratum 2 | 51 |
"Pharmacokinetic assay Cmax/D~Samples drawn at 5 timepoints: (0 (pre dose), 30min, 1 hour, 3 hours, and 6 hours post-dose) on two different days." (NCT02395666)
Timeframe: Samples drawn at 5 timepoints: (0 (pre dose), 30min, 1 hour, 3 hours, and 6 hours post-dose) on two different days
| Intervention | ng/mL (Mean) |
|---|---|
| Study Subjects Consented to PK Collection | 11958 |
To evaluate the preventative activity of DFMO as a single agent in patients with neuroblastoma who are in remission based on: Overall Survival (OS) (NCT02395666)
Timeframe: 2 Years
| Intervention | percentage of subjects without an event (Mean) |
|---|---|
| Stratum 1 | 97 |
| Stratum 2 | 84 |
"Tests (p-value) of the association of survival with ODC1 single nucleotide polymorphism rs2302616 genotype.~Blood: microRNA analysis as predictor of DFMO effect, ornithine decarboxylase (ODC) single nucleotide polymorphism (SNP) analysis in DNA isolated from nucleated cells" (NCT02395666)
Timeframe: 2 years
| Intervention | p-value (Number) |
|---|---|
| GG, GT, TT | 0.96 |
| GG or GT, TT | 0.58 |
| GG, GT or TT | 0.67 |
"Pharmacokinetic assay- tmax, hr~Samples drawn at 5 timepoints: (0 (pre dose), 30min, 1 hour, 3 hours, and 6 hours post-dose) on two different days" (NCT02395666)
Timeframe: 0 (pre dose), 30min, 1 hour, 3 hours, and 6 hours post-dose on two different days
| Intervention | hours (Mean) |
|---|---|
| Study Subjects Consented to PK Collection | 3.3 |
11 other studies available for biguanides and Neuroblastoma
| Article | Year |
|---|---|
The biguanide polyamine analog verlindamycin promotes differentiation in neuroblastoma via induction of antizyme.
Topics: Biguanides; Humans; N-Myc Proto-Oncogene Protein; Neuroblastoma; Ornithine Decarboxylase; Polyamines | 2022 |
Introduction of the 5-HT3B subunit alters the functional properties of 5-HT3 receptors native to neuroblastoma cells.
Topics: Animals; Biguanides; Calcium; Cell Differentiation; Cell Line; Dose-Response Relationship, Drug; Dru | 2003 |
Characterization of [3H]meta-chlorophenylbiguanide binding to 5-HT3 receptors in N1E-115 neuroblastoma cells.
Topics: Animals; Biguanides; Binding, Competitive; Electrophysiology; Mice; Neuroblastoma; Radioligand Assay | 1993 |
Differential binding characteristics of agonists at 5-HT3 receptor recognition sites in NG108-15 neuroblastoma-glioma cells labelled by [3H]-(S)-zacopride and [3H]granisetron.
Topics: Animals; Benzamides; Biguanides; Binding Sites; Binding, Competitive; Bridged Bicyclo Compounds; Bri | 1993 |
5-HT3 receptor-independent inhibition of the depolarization-induced 86Rb efflux from human neuroblastoma cells, TE671, by ondansetron.
Topics: Anti-Anxiety Agents; Benzamides; Benzofurans; Biguanides; Bridged Bicyclo Compounds, Heterocyclic; H | 1995 |
Direct inhibition of 5-hydroxytryptamine3 receptors by antagonists of L-type Ca2+ channels.
Topics: Biguanides; Binding, Competitive; Calcium; Calcium Channel Blockers; Calcium Channels; Calcium Chann | 1996 |
Native serotonin 5-HT3 receptors expressed in Xenopus oocytes differ from homopentameric 5-HT3 receptors.
Topics: Animals; Biguanides; Cell Differentiation; Dopamine; Female; Kinetics; Macromolecular Substances; Me | 1997 |
High calcium permeability of serotonin 5-HT3 receptors on presynaptic nerve terminals from rat striatum.
Topics: Animals; Biguanides; Calcium; Calcium Channel Blockers; Calcium Channels; Cell Membrane Permeability | 1998 |
Postsynaptic target regulates functional responses induced by 5-HT3 serotonin receptors on axonal varicosities of NG108-15 hybrid neuroblastoma cells.
Topics: Animals; Axons; Biguanides; Calcium; Cell Differentiation; Coculture Techniques; Culture Media, Cond | 2001 |
5-HT3 receptors in NG108-15 neuroblastoma x glioma cells: effect of the novel agonist 1-(m-chlorophenyl)-biguanide.
Topics: Animals; Biguanides; Binding, Competitive; Evoked Potentials; Glioma; Hybrid Cells; Imidazoles; Indo | 1992 |
The agonist properties of m-chlorophenylbiguanide and 2-methyl-5-hydroxytryptamine on 5-HT3 receptors in N1E-115 neuroblastoma cells.
Topics: Animals; Biguanides; Membrane Potentials; Mice; Neuroblastoma; Neurons; Radioligand Assay; Receptors | 1991 |